发明申请
US20120277238A1 PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE
审中-公开
含有金属杂环衍生物的药物组合物
- 专利标题: PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE
- 专利标题(中): 含有金属杂环衍生物的药物组合物
-
申请号: US13388296申请日: 2010-07-29
-
公开(公告)号: US20120277238A1公开(公告)日: 2012-11-01
- 发明人: Yuuki Tachibana , Masayoshi Miyagawa , Tsutomu Masuda , Tsuyoshi Hasegawa
- 申请人: Yuuki Tachibana , Masayoshi Miyagawa , Tsutomu Masuda , Tsuyoshi Hasegawa
- 申请人地址: JP Osaka-shi, Osaka
- 专利权人: Shionogi & Co., Ltd
- 当前专利权人: Shionogi & Co., Ltd
- 当前专利权人地址: JP Osaka-shi, Osaka
- 优先权: JP2009-178508 20090731
- 国际申请: PCT/JP2010/062804 WO 20100729
- 主分类号: A61K31/496
- IPC分类号: A61K31/496 ; C07D471/04 ; C07D491/052 ; C07D487/04 ; A61K31/4985 ; A61K31/404 ; A61K31/437 ; A61P11/06 ; A61P37/08 ; A61P11/00 ; A61P29/00 ; A61P17/06 ; A61P1/00 ; A61P9/10 ; A61P25/00 ; C07D403/06
摘要:
The present invention provides a compound which indicates a histamine H4 receptor modulating activity.A compound represented by a formula (I): wherein A ring is a ring represented by the following formula: wherein R1 is substituted or unsubstituted alkyl, etc., W is —O—, etc., n is an integer of 0 to 6; X is —N(R7)— or —O—; R7 is hydrogen, substituted or unsubstituted alkyl, etc.; Y is —C(R8)═ or —N═; R8 is hydrogen, substituted or unsubstituted alkyl, etc.; Z is ═O, ═S, etc.; B ring is a ring represented by the following formula: wherein R10 is each independently substituted or unsubstituted alkyl, halogen, hydroxy, substituted or unsubstituted alkyloxy, substituted or unsubstituted amino; R11, R12a and R12b are each independently hydrogen or substituted or unsubstituted alkyl, etc.; p is an integer of 0 to 4, or its pharmaceutically acceptable salt, or a solvate thereof.
信息查询
IPC分类: